Patrick Henno is a PhD graduated from the French University of Compiègne (1985).

​

In 1997, he founded a company named MAbgène which was bought by LFB in 2011 (now LFB Biomanufacturing), focused on the production of proteins and cell therapy developments as a CMO.

​

Headquarters and production unit have been settled in Alès and produced biomolecules according to GMP regulations.

​

He joined CELLforCURE as the executive general manager, from 2011 to 2013.

​

In 2013, he became a co-founder of Emercell SAS, company focused on the development of immunotherapy projects and the implementation of the first pharmaceutical development steps.